Tumor-directed Radiation Therapy for Patients With the Highest Risk Category of Localized Prostate Cancer

HYPO-RT-PC boost is is an open-label, multicentre, phase II trial evaluating safety and efficacy of real-time image-guided tumor-directed ultra-hypofractionated radiation boost and lymph node irradiation for patients with node-negative high risk localized prostate cancer.

Trial Details

NCT ID
NCT06220435
Phase
NA
Sponsor
Region Skane
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Ultra-hypofractionated radiotherapy regimen.
Locations (sample)
  • Lund, Sweden|55.70584,13.19321
  • Umeå, Sweden|63.82842,20.25972

Key Eligibility Criteria

  • Life expectancy \>5 years
  • Age ≥18 years
  • World Health Organization (WHO) performance status 0-2
  • Histological evidence of prostate cancer

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →